Why is Biogen Pharma falling/rising?

As of 23-Sep, Biogen Pharmachem Industries Ltd is currently priced at 0.89, showing no change (0.00%). The stock has underperformed in the short term, with a 1-week return of -1.11% compared to the Sensex's -0.34%. Over the past month, the stock has declined by 2.20%, while the Sensex has increased by 0.98%. Year-to-date, Biogen Pharma has experienced a significant drop of 24.58%, contrasting sharply with the Sensex's gain of 5.07%. Despite today's performance indicating that the stock outperformed its sector by 1.58%, it is trading below all key moving averages, which suggests a bearish trend. Additionally, there has been a rise in investor participation, with delivery volume increasing by 16.06% against the 5-day average, indicating some interest in the stock despite its overall downward trajectory.
In the broader market context, Biogen Pharma's recent performance reflects a challenging environment, particularly given its substantial year-to-date decline of 24.58% against the Sensex's positive performance. The stock's inability to maintain momentum, as evidenced by its trading below moving averages, suggests that investor sentiment remains cautious. The overall market has shown resilience, with the Sensex gaining 5.07% year-to-date, while Biogen Pharma's long-term performance remains strong with a 286.96% increase over the past five years. However, the stark contrast in returns highlights the stock's struggles relative to the broader market, indicating that external factors may be influencing investor confidence negatively.